NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ:NTLA).
Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
CLASS PERIOD: July 30, 2024 to January 8, 2025
ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning Intellia’s Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Defendants’ statements included, among other things, confidence in the Company’s timeline for the aforementioned study, specifically that Intellia expected to dose the first patient in the second half of 2024. Defendants failed to disclose inter alia that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a …
